Bacteremia is an indication for drug development with over 190 pipeline drugs currently active. According to GlobalData, preregistered drugs for Bacteremia have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Bacteremia compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Likelihood of Approval Analysis for Bacteremia

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Bacteremia overview

Bacteremia is a medical condition characterized by the presence of bacteria in the bloodstream. It can occur due to various causes, such as wounds, infections, dental or medical procedures, or injections. Bacteremia can be asymptomatic or cause symptoms such as fever, chills, and low blood pressure. Bacteremia can lead to serious complications, such as sepsis, endocarditis, meningitis, or osteomyelitis, if not treated promptly with antibiotics. The diagnosis of bacteremia is made by blood culture, which identifies the type and number of bacteria in the blood. The treatment of bacteremia depends on the source and severity of the infection, as well as the susceptibility of the bacteria to antibiotics.

For a complete picture of PTSR and LoA scores for drugs in Bacteremia, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.